

# ForPatients

by Roche

Non Hodgkin Lymphoma (NHL)

## A Study of Atezolizumab in Combination With an Immunotherapy Agent Investigated With or Without Anti-Cd20 Therapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

**Trial Status**  
Withdrawn

**Trial Runs In**  
1 Countries

**Trial Identifier**  
NCT03369964 2017-002587-41  
GO40150

---

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

### *Trial Summary:*

This study will investigate the safety, pharmacology, and activity of atezolizumab in combination with immunotherapy agents with or without an anti-CD20 agent (i.e., obinutuzumab) in patients with relapsed or refractory (R/R) follicular lymphoma (FL). The first immunotherapy molecule investigated will be emactuzumab (Arm A) in two combinations.

**Hoffmann-La Roche**  
Sponsor

**Phase 1**  
Phase

---

**NCT03369964 2017-002587-41 GO40150**  
Trial Identifiers

---

### *Eligibility Criteria:*

**Gender**  
All

**Age**  
≥18 Years

**Healthy Volunteers**  
No

---